Literature DB >> 17060126

Blockade of tumor necrosis factor-alpha-converting enzyme improves experimental small intestinal damage by decreasing matrix metalloproteinase-3 production in rats.

Hiroshi Matsumoto1, Hideki Koga, Mitsuo Iida, Ken-Ichi Tarumi, Minoru Fujita, Ken Haruma.   

Abstract

OBJECTIVE: Tumor necrosis factor (TNF)-alpha-converting enzyme (TACE), which has been purified, regulates maturity of TNF-alpha. Matrix metalloproteinases (MMPs) play a key role in various inflammatory conditions. The incidence of intestinal damage has increased, but the mechanism and treatment have not been well understood. The purpose of this study was to investigate the roles of TACE and MMP in indomethacin (Indo)-induced intestinal damage as well as the therapeutic effects of TACE inhibitor and selective MMP inhibitor (sMMPi) on this intestinal damage in rats.
MATERIAL AND METHODS: In the first experiment, serial changes in intestinal ulcers and the production of MMP were investigated. In the second experiment, we assessed the effect of three TACE and/or MMP inhibitors and the production of TNF-alpha, TACE, MMP-3, -9 and tissue inhibitor of MMP (TIMP)-1. The rats were divided into five groups: a control group, and four groups that received Indo alone, Indo plus TACE inhibitor (GM6001), Indo plus a selective MMP-3 inhibitor and Indo plus an MMP-9/13 inhibitor, respectively.
RESULTS: MMP-3 was overexpressed at 24 h after Indo administration, when intestinal injury was most prominent macroscopically and microscopically. GM6001 significantly decreased ulcer severity and suppressed MMP-3 in a dose-dependent fashion. The selective MMP-3 inhibitor dose-dependently ameliorated intestinal damage to the same degree as GM6001, but the MMP-9 inhibitor had no effect on the injury.
CONCLUSIONS: MMP-3 inhibition ameliorates intestinal damage without apparently affecting either TNF-alpha or TACE production and the dose-response curve suggests that the beneficial effect of the so-called TACE inhibitor is actually mainly mediated via MMP-3 inhibition rather than TNF-alpha inhibition.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17060126     DOI: 10.1080/00365520600684571

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  7 in total

1.  Nonselective matrix metalloproteinase but not tumor necrosis factor-α inhibition effectively preserves the early critical colon anastomotic integrity.

Authors:  Magnus S Ågren; Thomas L Andersen; Line Andersen; Christine Bruun Schiødt; Vikas Surve; Troels T Andreassen; Juha Risteli; Lennart E Franzén; Jean-Marie Delaissé; Anne-Marie Heegaard; Lars N Jorgensen
Journal:  Int J Colorectal Dis       Date:  2010-12-31       Impact factor: 2.571

Review 2.  Inhibition of MMPs and ADAM/ADAMTS.

Authors:  Charles J Malemud
Journal:  Biochem Pharmacol       Date:  2019-02-28       Impact factor: 5.858

3.  Inhibition of matrix metalloproteinase activity prevents increases in myocardial tumor necrosis factor-alpha.

Authors:  David B Murray; Scott P Levick; Gregory L Brower; Joseph S Janicki
Journal:  J Mol Cell Cardiol       Date:  2010-04-18       Impact factor: 5.000

4.  Effects of metalloproteinase inhibition in a murine model of renal ischemia-reperfusion injury.

Authors:  Katherine B Novak; Hau D Le; Emily R Christison-Lagay; Vania Nose; Robert J Doiron; Marsha A Moses; Mark Puder
Journal:  Pediatr Res       Date:  2010-03       Impact factor: 3.756

5.  Mucosal gene therapy using a pseudotyped lentivirus vector encoding murine interleukin-10 (mIL-10) suppresses the development and relapse of experimental murine colitis.

Authors:  Hiroshi Matsumoto; Kazunori Haga; Izumi Ohno; Kei Hiraoka; Takahiro Kimura; Kip Hermann; Noriyuki Kasahara; Peter Anton; Ian McGowan
Journal:  BMC Gastroenterol       Date:  2014-04-08       Impact factor: 3.067

6.  ADAM proteases involved in inflammation are differentially altered in patients with gastritis or ulcer.

Authors:  Nuray Erin; Sema Türker; Özlem Elpek; Bülent Yildirim
Journal:  Exp Ther Med       Date:  2017-12-12       Impact factor: 2.447

7.  Urinary IL-8 is a marker of early and long-term graft function after renal transplantation.

Authors:  Ewa Kwiatkowska; Leszek Domański; Joanna Bober; Krzysztof Safranow; Jolanta Szymańska-Pasternak; Aneta Sulecka; Andrzej Pawlik; Kazimierz Ciechanowski; Sebastian Kwiatkowski
Journal:  Ren Fail       Date:  2017-11       Impact factor: 2.606

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.